Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.

Amy A MehtaLevi N KanuShalini Sood-MendirattaRichard QuinonesAnjali HawkinsRichard A LehrerKiran MalhotraRobert PapasDavid HillmanJacob T WilenskyAhmad A ArefThasarat Sutabutr VajaranantDeepak P Edward

Published in: European journal of ophthalmology (2021)

Similar to monotherapy, netarsudil and latanoprostene bunod demonstrated efficacy in lowering IOP when used as adjunctive therapy.

Keyphrases

combination therapy
open label
randomized controlled trial
mesenchymal stem cells
cataract surgery